#3-58E. Fertility Preserved: First Report of Spontaneous Pregnancies After CAR-T in SLE (Arthritis Rheumatol, 2026)

How does the revolutionary advent of CAR-T cell therapy impact reproductive potential in young patients with autoimmune diseases? This episode examines a landmark brief report detailing the first known cases of successful spontaneous pregnancies following dual-target BCMA/CD19 CAR-T therapy in a 24-year-old patient with refractory systemic lupus erythematosus (SLE). After achieving deep, drug-free remission, the patient delivered two healthy infants via vaginal birth without experiencing disease flares. The most significant clinical takeaway is the verified absence of CAR-T DNA in the placenta, breast milk, and neonatal blood, suggesting that this therapy preserves fertility and carries a minimal risk of vertical transmission or neonatal immune disruption. This stands in promising contrast to the known gonadotoxicity of traditional cytotoxic agents like cyclophosphamide. However, critical appraisal is necessary; this is a single case report (N=1), and while the outcomes were favorable, larger cohorts and longer follow-up are required to firmly establish safety guidelines. For rheumatologists, this study is immediately relevant for counseling young patients, offering preliminary evidence that CAR-T therapy may be a viable option for those prioritizing future family planning.

Citation: Jiang Q, Wang M, Wang M, et al. Successful Spontaneous Pregnancies and Healthy Neonates After Dual-Target CAR–T Cell Therapy in Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70070

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.